Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING
Authors
Keywords
-
Journal
Cell Reports
Volume 36, Issue 3, Pages 109412
Publisher
Elsevier BV
Online
2021-07-22
DOI
10.1016/j.celrep.2021.109412
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity
- (2019) Anne Margriet Heijink et al. Nature Communications
- Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
- (2019) Zebin Wang et al. Scientific Reports
- Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
- (2019) Triparna Sen et al. Cancer Discovery
- PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
- (2019) Constantia Pantelidou et al. Cancer Discovery
- Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors
- (2019) Denarda Dangaj et al. CANCER CELL
- BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
- (2019) Timo Reisländer et al. Nature Communications
- Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
- (2019) Shaveta Vinayak et al. JAMA Oncology
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
- (2019) Panagiotis A. Konstantinopoulos et al. JAMA Oncology
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- (2019) Isabelle Ray-Coquard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
- (2018) Ilary Ruscito et al. BRITISH JOURNAL OF CANCER
- Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment
- (2018) Elham Azizi et al. CELL
- The Immune Landscape of Cancer
- (2018) Vésteinn Thorsson et al. IMMUNITY
- Chromosomal instability drives metastasis through a cytosolic DNA response
- (2018) Samuel F. Bakhoum et al. NATURE
- A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
- (2018) Daniela S. Thommen et al. NATURE MEDICINE
- Copy number signatures and mutational processes in ovarian carcinoma
- (2018) Geoff Macintyre et al. NATURE GENETICS
- A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
- (2018) Livnat Jerby-Arnon et al. CELL
- Structural insights into the duplex DNA processing of TREX2
- (2018) Hiu-Lo Cheng et al. NUCLEIC ACIDS RESEARCH
- PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
- (2018) Liya Ding et al. Cell Reports
- Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors
- (2018) Sadegh Saghafinia et al. Cell Reports
- BRCA1-Dependent Transcriptional Regulation: Implication in Tissue-Specific Tumor Suppression
- (2018) Xiaowen Zhang et al. Cancers
- PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer
- (2018) Roman M. Chabanon et al. JOURNAL OF CLINICAL INVESTIGATION
- Mitotic progression following DNA damage enables pattern recognition within micronuclei
- (2017) Shane M. Harding et al. NATURE
- Cytoplasmic chromatin triggers inflammation in senescence and cancer
- (2017) Zhixun Dou et al. NATURE
- Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes
- (2017) Yi Kan Wang et al. NATURE GENETICS
- DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
- (2017) Claire Vanpouille-Box et al. Nature Communications
- Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions
- (2017) Susan M. Domchek Cancer Discovery
- Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
- (2017) et al. JAMA Oncology
- CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity
- (2017) Josephine B. Walton et al. Scientific Reports
- A computational strategy to adjust for copy number in tumor Hi-C data
- (2016) Hua-Jun Wu et al. BIOINFORMATICS
- CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma
- (2016) J. Walton et al. CANCER RESEARCH
- Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer
- (2016) Hui Zhang et al. CELL
- Genetic characterization of early onset ovarian carcinoma
- (2016) Sarah S. Bernards et al. GYNECOLOGIC ONCOLOGY
- Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
- (2016) Eileen E. Parkes et al. JNCI-Journal of the National Cancer Institute
- Replication fork stability confers chemoresistance in BRCA-deficient cells
- (2016) Arnab Ray Chaudhuri et al. NATURE
- The Perseus computational platform for comprehensive analysis of (prote)omics data
- (2016) Stefka Tyanova et al. NATURE METHODS
- Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line
- (2016) Jaine K. Blayney et al. NUCLEIC ACIDS RESEARCH
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
- (2016) Kyle C. Strickland et al. Oncotarget
- Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
- (2016) Eileen E. Parkes et al. JNCI-Journal of the National Cancer Institute
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
- (2015) Katherine B. Chiappinelli et al. CELL
- DNA Damage Primes the Type I Interferon System via the Cytosolic DNA Sensor STING to Promote Anti-Microbial Innate Immunity
- (2015) Anetta Härtlova et al. IMMUNITY
- Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation
- (2015) S. Liu et al. SCIENCE
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
- (2015) P. A. Konstantinopoulos et al. Cancer Discovery
- HTSeq--a Python framework to work with high-throughput sequencing data
- (2014) S. Anders et al. BIOINFORMATICS
- Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors—Response
- (2014) Jaikumar Duraiswamy et al. CANCER RESEARCH
- Intrinsic Self-DNA Triggers Inflammatory Disease Dependent on STING
- (2014) Jeonghyun Ahn et al. JOURNAL OF IMMUNOLOGY
- Cytosolic-DNA-Mediated, STING-Dependent Proinflammatory Gene Induction Necessitates Canonical NF- B Activation through TBK1
- (2014) T. Abe et al. JOURNAL OF VIROLOGY
- Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ
- (2014) Jürgen Cox et al. MOLECULAR & CELLULAR PROTEOMICS
- A promoter-level mammalian expression atlas
- (2014) NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
- (2013) Y. Liao et al. BIOINFORMATICS
- Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with BRCA1 and BRCA2 Mutations
- (2013) J. George et al. CLINICAL CANCER RESEARCH
- Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
- (2013) Kathryn P. Pennington et al. CLINICAL CANCER RESEARCH
- Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
- (2013) Gabriela Bindea et al. IMMUNITY
- BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation
- (2013) Britta Stordal et al. Molecular Oncology
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- HiCNorm: removing biases in Hi-C data via Poisson regression
- (2012) Ming Hu et al. BIOINFORMATICS
- STAR: ultrafast universal RNA-seq aligner
- (2012) Alexander Dobin et al. BIOINFORMATICS
- BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma
- (2012) Jessica N McAlpine et al. MODERN PATHOLOGY
- The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
- (2011) M J M Gooden et al. BRITISH JOURNAL OF CANCER
- BRCA1 tumour suppression occurs via heterochromatin-mediated silencing
- (2011) Quan Zhu et al. NATURE
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Probabilistic modeling of Hi-C contact maps eliminates systematic biases to characterize global chromosomal architecture
- (2011) Eitan Yaffe et al. NATURE GENETICS
- CD4+ T Cells Elicit Host Immune Responses to MHC Class II- Ovarian Cancer through CCL5 Secretion and CD40-Mediated Licensing of Dendritic Cells
- (2010) Y. C. Nesbeth et al. JOURNAL OF IMMUNOLOGY
- RNA Polymerase III Detects Cytosolic DNA and Induces Type I Interferons through the RIG-I Pathway
- (2009) Yu-Hsin Chiu et al. CELL
- MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification
- (2008) Jürgen Cox et al. NATURE BIOTECHNOLOGY
- PID: the Pathway Interaction Database
- (2008) Carl F. Schaefer et al. NUCLEIC ACIDS RESEARCH
- Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
- (2007) Ronald J Buckanovich et al. NATURE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started